Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.65 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.60 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.60 |
| ▸ | MAPT | P10636 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.58 |
| ▸ | SQLE | Q14534 | 3/20 | 0.56 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.53 |
| ▸ | GGPS1 | O95749 | 1/20 | 0.53 |
| ▸ | FDFT1 | P37268 | 1/20 | 0.53 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31406762 | 0.98 | KMT2A (0.70) | KMT2AMEN1CYP3A4ALOX15MAPT | |
| SCHEMBL31406758 | 0.98 | KMT2A (0.70) | KMT2AMEN1CYP3A4ALOX15MAPT | |
| SCHEMBL31406757 | 0.98 | KMT2A (0.70) | KMT2AMEN1CYP3A4ALOX15MAPT | |
| SCHEMBL10445541 | 0.89 | KMT2A (0.58) | KMT2AMEN1CYP3A4ALOX15MAPT | |
| SCHEMBL10445540 | 0.89 | KMT2A (0.58) | KMT2AMEN1CYP3A4ALOX15MAPT | |
| SCHEMBL16892803 | 0.88 | KMT2A (0.57) | KMT2AMEN1CYP3A4ALOX15MAPT | |
| SCHEMBL16892784 | 0.88 | KMT2A (0.57) | KMT2AMEN1CYP3A4ALOX15MAPT | |
| SCHEMBL15516075 | 0.88 | KMT2A (0.57) | KMT2AMEN1CYP3A4ALOX15MAPT | |
| SCHEMBL11645968 | 0.86 | SQLE (0.57) | KMT2AMEN1CYP3A4ALOX15MAPT | |
| SCHEMBL11645972 | 0.86 | SQLE (0.57) | KMT2AMEN1CYP3A4ALOX15MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-9291030-A | — | — | None | — | — | JP | disclosed |
| JP-10218764-A | — | — | None | — | — | JP | disclosed |
| JP-11130670-A | — | — | None | — | — | JP | disclosed |
| JP-2011207802-A | BIRTH RATE INCREASE PROMOTER APPLIED TO MAMMALS, TRANQUILIZER APPLIED TO MAMMALS, AND FEED FOR LIVESTOCK | NAGASAKIKEN KORITSU DAIGAKU HOJIN | 2011-10-20 | — | — | JP | disclosed |
| US-20090208458-A1 | Transcriptional inhibitor for human k-ras gene | NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (JP) | 2009-08-20 | — | — | US | disclosed |
| US-6048882-A | ISOPRENYLAMINE COMPOUND | NISSHIN FLOUR MILLING CO., LTD. (JP) | 2000-04-11 | — | — | US | disclosed |
| JP-H11130670-A | OSTEOPOROSIS THERAPEUTIC AGENT | OYO SEIKAGAKU KENKYUSHO | 1999-05-18 | — | — | JP | disclosed |
| JP-H10218764-A | PANCREATIC CANCER-TREATING AGENT | TORAY IND INC | 1998-08-18 | — | — | JP | disclosed |
| EP-0810201-A1 | PREVENTIVE/REMEDY FOR LIVER DISEASE | NISSHIN FLOUR MILLING CO., LTD. (JP) | 1997-12-03 | — | — | EP | disclosed |
| JP-H09291030-A | ANTICANCER DRUG CONTAINING GERANYLGERANYLAMINE DERIVATIVE AS ACTIVE INGREDIENT | KURARAY CO LTD | 1997-11-11 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090208458-A1 | Transcriptional inhibitor for human k-ras gene | MYCBP, UPF1, MYC | KMT2A 614/4885MEN1 1751/4885CYP3A4 4078/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.